Innocare (688428.SH) disclosed its semi-annual report for 2024, and the company achieved revenue of 4... in the reporting period.
According to the semi-annual report for 2024 released by Innocare (688428.SH), the company achieved operating revenue of 0.42 billion yuan (RMB) in the reporting period, an increase of 11.17% year-on-year. The net loss attributable to shareholders of the listed company was 0.262 billion yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.253 billion yuan, with a narrower loss compared to the same period last year.
In the first half of 2024, the company's core product, Osimertinib (Innocare), achieved strong growth with sales of 0.417 billion yuan, a year-on-year increase of 30.02%, and a year-on-year increase of 48.81% in the second quarter of 2024. In addition, the company continues to increase its investment in new technology platform construction, preclinical research, and clinical trials, with research and development investment of 0.421 billion yuan, an increase of 0.06 billion yuan compared to the same period last year.